About Shire (NASDAQ:SHPG)
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company's segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases. Its Hematology products include ADVATE (Antihemophilic Factor (Recombinant)), ADYNOVATE/ADYNOVI (Antihemophilic Factor (Recombinant), PEGylated)), RIXUBIS (Coagulation Factor IX (Recombinant)), VONVENDI (von Willebrand factor (Recombinant)) and FEIBA (Anti-Inhibitor Coagulant Complex). Its Genetic Diseases products include CINRYZE (C1 esterase inhibitor (human)), FIRAZYR (icatibant), ELAPRASE (idursulfase), REPLAGAL (agalsidase alfa) and VPRIV (velaglucerase alfa).
Industry, Sector and Symbol
Trailing P/E Ratio9.19715302491103
Forward P/E Ratio8.45
Sales & Book Value
Annual Sales$15.16 billion
Price / Sales2.58
Cash Flow$22.62 per share
Price / Cash5.69
Book Value$119.43 per share
Price / Book1.08
Net Income$4.27 billion
Return on Equity14.19%
Return on Assets6.86%
Shire (NASDAQ:SHPG) Frequently Asked Questions
What is Shire's stock symbol?
Shire trades on the NASDAQ under the ticker symbol "SHPG."
How often does Shire pay dividends? What is the dividend yield for Shire?
Shire announced a semiannual dividend on Friday, February 16th. Stockholders of record on Friday, March 9th will be paid a dividend of $0.8937 per share on Tuesday, April 24th. This represents a dividend yield of 1.33%. The ex-dividend date is Thursday, March 8th. This is a positive change from Shire's previous semiannual dividend of $0.15. View Shire's Dividend History.
How were Shire's earnings last quarter?
Shire PLC (NASDAQ:SHPG) issued its quarterly earnings data on Wednesday, February, 14th. The biopharmaceutical company reported $3.98 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $3.86 by $0.12. The biopharmaceutical company had revenue of $4.14 billion for the quarter. Shire had a return on equity of 14.19% and a net margin of 28.17%. The company's quarterly revenue was up 8.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.37 earnings per share. View Shire's Earnings History.
When will Shire make its next earnings announcement?
What guidance has Shire issued on next quarter's earnings?
Shire issued an update on its FY18 earnings guidance on Wednesday, February, 14th. The company provided EPS guidance of $14.90-15.50 for the period, compared to the Thomson Reuters consensus estimate of $16.02. The company issued revenue guidance of 15.4-15.9 billion, compared to the consensus revenue estimate of $15.47 billion.
Where is Shire's stock going? Where will Shire's stock price be in 2018?
17 Wall Street analysts have issued twelve-month price objectives for Shire's shares. Their predictions range from $150.00 to $245.00. On average, they anticipate Shire's stock price to reach $204.00 in the next twelve months. View Analyst Ratings for Shire.
What are Wall Street analysts saying about Shire stock?
Here are some recent quotes from research analysts about Shire stock:
- 1. Cantor Fitzgerald analysts commented, "Shire reported 4Q17 results and provided its 2018 financial guidance this morning. The report was mixed relative to expectations. Investors that we spoke with were anticipating a strong 4Q17 with no surprises, but hoping for 2018 consensus sales and EPS that would at least bracket consensus (which did not happen)." (2/14/2018)
- 2. According to Zacks Investment Research, "The sales of Mydayis did not meet Shire’s expectation while strong performance of Vyvanse, Cinryze and Elaprase continue to drive Shire’s top line. The label expansion of Cinryze in paediatrics and conditional approval of Natpara in Europe should continue to drive the top line going ahead. The hematology and immunology segment, acquired from Baxalta, gave a major boost to product sales. The approval of Xiidra has boosted the company’s ophthalmology portfolio. However, the adult ADHD space is one of the largest and fastest growing segments of the market but is highly genericized. Supply shortage for Cinryze and generic competition for Lialda had an unfavorable impact on the top line. Moreover, its shares have underperformed the industry in the past one year. Estimates have increased ahead of the Q4 earnings results. The company has a positive record of earnings surprises in recent quarters." (2/6/2018)
- 3. Royal Bank of Canada analysts commented, "We don’t have a clue on the contribution of PhotonBlade in the qtr. FY18 guidance will be critical. Consensus currently is ~$52M. A number below consensus will be parsed almost immediately as to implied PhotonBlade / non- PhotonBlade growth." (2/5/2018)
Who are some of Shire's key competitors?
Some companies that are related to Shire include Celgene (CELG), Biogen (BIIB), Allergan (AGN), Vertex Pharmaceuticals (VRTX), Takeda Pharmaceutical (TKPYY), Zoetis (ZTS), Illumina (ILMN), Regeneron Pharmaceuticals (REGN), Astellas Pharma (ALPMY), Actelion (ALIOF), Alexion Pharmaceuticals (ALXN), Mylan (MYL), Eisai (ESALY), Incyte (INCY), Teva Pharmaceutical Industries (TEVA), Nektar Therapeutics (NKTR), Sino Biopharmaceut (SBMFF) and BioMarin Pharmaceutical (BMRN).
Who are Shire's key executives?
Shire's management team includes the folowing people:
- Flemming Ornskov M.D., Chief Executive Officer, Executive Director (Age 59)
- John Miller, Interim Chief Financial Officer
- Joanne Cordeiro, Chief Human Resource Officer
- Andreas Busch Ph.D., Executive Vice President - Head of Research and Development, Chief Scientific Officer (Age 54)
- Gisele Dion, Chief Accounting Officer, Corporate Controller (Age 51)
- William Mordan, General Counsel, Company Secretary (Age 47)
- Howard Mayer M.D., Chief Medical Officer
- Perry Sternberg, Head - U.S. Commercial (Age 48)
- Kim Stratton, Head - International Commercial (Age 56)
- Philip J. Vickers, Head - Research and Development (Age 56)
Has Shire been receiving favorable news coverage?
News stories about SHPG stock have trended very positive on Wednesday, according to Accern. Accern ranks the sentiment of media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Shire earned a media sentiment score of 0.56 on Accern's scale. They also assigned headlines about the biopharmaceutical company an impact score of 45.00 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next several days.
Who are Shire's major shareholders?
Shire's stock is owned by a number of of institutional and retail investors. Top institutional investors include Boston Partners (0.78%), The Manufacturers Life Insurance Company (0.61%), Maverick Capital Ltd. (0.55%), BlackRock Inc. (0.35%), Rockefeller Financial Services Inc. (0.19%) and ING Groep NV (0.17%). View Institutional Ownership Trends for Shire.
Which institutional investors are selling Shire stock?
SHPG stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Advisers LP, Maverick Capital Ltd., Jennison Associates LLC, Millennium Management LLC, Deutsche Bank AG, BlackRock Inc., Capital Fund Management S.A. and York Capital Management Global Advisors LLC. View Insider Buying and Selling for Shire.
Which institutional investors are buying Shire stock?
SHPG stock was acquired by a variety of institutional investors in the last quarter, including Boston Partners, ING Groep NV, FNY Partners Fund LP, Brandywine Global Investment Management LLC, Snow Capital Management LP, Bank of Montreal Can, Delek Group Ltd. and OLD Mission Capital LLC. View Insider Buying and Selling for Shire.
How do I buy shares of Shire?
Shares of SHPG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Shire's stock price today?
One share of SHPG stock can currently be purchased for approximately $128.73.
How big of a company is Shire?
Shire has a market capitalization of $39.22 billion and generates $15.16 billion in revenue each year. The biopharmaceutical company earns $4.27 billion in net income (profit) each year or $14.05 on an earnings per share basis. Shire employs 23,044 workers across the globe.
How can I contact Shire?
Shire's mailing address is BLOCK 2 MIESIAN PLAZA 50-58 BAGGOT STREET LOWER, Dublin L2, D02. The biopharmaceutical company can be reached via phone at 353-1609-6000 or via email at [email protected]
MarketBeat Community Rating for Shire (SHPG)MarketBeat's community ratings are surveys of what our community members think about Shire and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Shire (NASDAQ:SHPG) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Buy||Buy||Buy||Buy|
|Consensus Rating Score: ||2.71||2.69||2.57||2.70|
|Ratings Breakdown: ||0 Sell Rating(s)|
5 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
5 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
6 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
6 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$204.00||$205.00||$212.18||$220.91|
|Price Target Upside: ||58.47% upside||52.92% upside||34.59% upside||39.94% upside|
Shire (NASDAQ:SHPG) Consensus Price Target History
Shire (NASDAQ:SHPG) Analyst Ratings History
(Data available from 3/21/2016 forward)
Shire (NASDAQ:SHPG) Earnings History and Estimates Chart
Shire (NASDAQ SHPG) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/1/2018|| || || || || || || || |
|5/2/2017||Q1 17||$3.22||$3.63||$3.57 billion||View||Listen|
|2/16/2017||Q416||$3.24||$3.37||$3.78 billion||$3.81 billion||View||N/A|
|11/1/2016||Q316||$3.21||$3.17||$3.57 billion||$3.45 billion||View||N/A|
|8/2/2016||Q216||$3.03||$3.38||$2.28 billion||$2.43 million||View||N/A|
|4/29/2016||Q1||$3.05||$3.19||$1.71 billion||$1.71 billion||View||Listen|
|2/11/2016||Q415||$2.89||$2.97||$1.69 million||$1.72 billion||View||Listen|
|10/23/2015||Q315||$2.87||$3.24||$1.63 billion||$1.58 billion||View||Listen|
|7/23/2015||Q215||$2.81||$2.63||$1.59 billion||$1.56 billion||View||Listen|
|4/30/2015||Q115||$2.56||$2.84||$1.47 billion||$1.49 billion||View||N/A|
|2/12/2015||Q115||$2.68||$2.63||$1.53 billion||$1.58 billion||View||N/A|
|10/24/2014||Q314||$2.47||$2.93||$1.46 billion||$1.55 billion||View||Listen|
|7/18/2014||Q214||$2.45||$2.67||$1.45 billion||$1.50 billion||View||N/A|
|5/1/2014||Q114||$2.22||$2.36||$1.38 billion||$1.35 billion||View||N/A|
|2/13/2014||Q413||$2.02||$2.26||$1.28 billion||$1.33 billion||View||N/A|
|10/24/2013||Q213||$1.65||$1.77||$1.23 billion||$1.24 billion||View||N/A|
|7/25/2013||$1.60||$1.79||$1.21 billion||$1.28 billion||View||N/A|
|5/2/2013||Q113||$1.56||$1.63||$1.21 billion||$1.16 billion||View||N/A|
|2/14/2013||Q412||$1.58||$1.58||$1.20 billion||$1.20 billion||View||N/A|
Shire (NASDAQ:SHPG) Earnings Estimates
2018 EPS Consensus Estimate: $15.73
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Shire (NASDAQ:SHPG) Dividend Information
|Payout Ratio:||7.47% (Trailing 12 Months of Earnings) |
6.89% (Based on This Year's Estimates)
6.45% (Based on Next Year's Estimates)
Shire (NASDAQ:SHPG) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Insider Trading History for Shire (NASDAQ SHPG)
No insider trades for this company have been tracked by MarketBeat.com
Shire (NASDAQ SHPG) News Headlines
|Shire plc : New Data Presented at the Endocrine Society's 2018 Annual Meeting Advances Understanding of the Rare ... - GlobeNewswire (press release)|
www.globenewswire.com - March 20 at 8:22 AM
|Shire plc : New Data Presented at the Endocrine Society's 2018 Annual Meeting Advances Understanding of the Rare Disease Chronic Hypoparathyroidism|
finance.yahoo.com - March 20 at 8:22 AM
|Quotidian Technical Highlights on Selected Drug Makers Stocks -- Sanofi, Shire, TherapeuticsMD, and Zogenix - PR Newswire (press release)|
www.prnewswire.com - March 19 at 8:17 AM
|Shire plc : Elections for the interim dividend in respect of the six months to December 31, 2017 - GlobeNewswire (press release)|
globenewswire.com - March 13 at 8:19 AM
|Shire To Present Advancements In Chronic Hypoparathyroidism Research - Nasdaq|
www.nasdaq.com - March 12 at 8:36 AM
|Shire to Highlight Advancements in Chronic Hypoparathyroidism Research at the Endocrine Society's 2018 Annual ... - GlobeNewswire (press release)|
globenewswire.com - March 12 at 8:36 AM
|Shire plc (SHPG) Ex-Dividend Date Scheduled for March 08, 2018 - Nasdaq|
www.nasdaq.com - March 8 at 8:17 AM
|Cantor Fitzgerald Analysts Give Shire (SHPG) a $222.00 Price Target|
www.americanbankingnews.com - March 7 at 4:42 PM
|Shire PLC (SHPG) Expected to Announce Quarterly Sales of $3.80 Billion|
www.americanbankingnews.com - March 7 at 3:52 PM
|MD Sass Investors Services Inc. Sells 49,184 Shares of Shire PLC (SHPG)|
www.americanbankingnews.com - March 6 at 2:53 PM
|Prisma Capital Partners LP Invests $7.37 Million in Shire PLC (SHPG) Stock|
www.americanbankingnews.com - March 6 at 9:10 AM
|Caladrius Biosciences Acquires an Exclusive License to a Late Stage CD34+ Cell Therapy Program for the Treatment of Refractory Angina|
finance.yahoo.com - March 6 at 8:12 AM
|FDA accepts Shire's marketing application for CIC med prucalopride, action date December 21|
seekingalpha.com - March 5 at 5:52 PM
|Snow Capital Management LP Takes Position in Shire PLC (SHPG)|
www.americanbankingnews.com - March 5 at 4:01 PM
|Zacks: Analysts Anticipate Shire PLC (SHPG) Will Announce Earnings of $3.58 Per Share|
www.americanbankingnews.com - March 5 at 11:46 AM
|SHIRE LAUNCHES MYPKFIT(TM) FOR ADVATE® [ANTIHEMOPHILIC FACTOR (RECOMBINANT)] IN THE US - GlobeNewswire (press release)|
www.globenewswire.com - March 5 at 8:13 AM
|OppenheimerFunds Inc. Boosts Position in Shire PLC (SHPG)|
www.americanbankingnews.com - March 4 at 12:10 PM
|Shire PLC (SHPG) Shares Sold by First Republic Investment Management Inc.|
www.americanbankingnews.com - March 4 at 11:46 AM
|With A Recent ROE Of 11.76%, Can Shire plc (LON:SHP) Catch Up To Its Industry?|
finance.yahoo.com - March 4 at 8:12 AM
|Shire (SHPG) Upgraded to "Sell" at BidaskClub|
www.americanbankingnews.com - March 3 at 10:02 PM
|Shire PLC (SHPG) Shares Sold by Lazard Asset Management LLC|
www.americanbankingnews.com - March 3 at 1:22 PM
|State of Tennessee Treasury Department Purchases Shares of 30,499 Shire PLC (SHPG)|
www.americanbankingnews.com - March 3 at 10:12 AM
|Sei Investments Co. Grows Position in Shire PLC (SHPG)|
www.americanbankingnews.com - March 3 at 8:00 AM
|UBS Asset Management Americas Inc. Has $27.46 Million Stake in Shire PLC (SHPG)|
www.americanbankingnews.com - March 2 at 7:52 PM
|Reviewing Shire (SHPG) and Santarus (SNTS)|
www.americanbankingnews.com - March 2 at 7:12 PM
|Eaton Vance Management Boosts Holdings in Shire PLC (SHPG)|
www.americanbankingnews.com - March 2 at 11:53 AM
|Shire PLC (SHPG) Holdings Lifted by Brown Advisory Inc.|
www.americanbankingnews.com - March 2 at 5:10 AM
|Shire PLC (SHPG) Shares Sold by Maverick Capital Ltd.|
www.americanbankingnews.com - March 1 at 3:56 PM
|FDA accepts Shire's Cal-PEG marketing application for ALL, action date December 22|
seekingalpha.com - February 28 at 6:06 PM
|Shire PLC (SHPG) Position Trimmed by Eagle Global Advisors LLC|
www.americanbankingnews.com - February 28 at 2:26 PM
|FDx Advisors Inc. Lowers Holdings in Shire PLC (SHPG)|
www.americanbankingnews.com - February 28 at 10:52 AM
|US FDA Accepts Shire's Biologics License Application for Calaspargase Pegol (Cal-PEG) for Acute Lymphoblastic ... - GlobeNewswire (press release)|
globenewswire.com - February 28 at 8:13 AM
|Shire PLC (SHPG) Shares Sold by Ashfield Capital Partners LLC|
www.americanbankingnews.com - February 28 at 4:40 AM
|Oak Grove Capital LLC Takes Position in Shire PLC (SHPG)|
www.americanbankingnews.com - February 26 at 3:55 PM
|Blog Exposure - Shire Gets BLA and Priority Review Status from FDA for Lanadelumab for the Prevention of HAE Attacks|
finance.yahoo.com - February 26 at 8:13 AM
|Shire PLC (SHPG) Shares Bought by MRJ Capital Inc.|
www.americanbankingnews.com - February 25 at 2:24 PM
|Pinnacle Associates Ltd. Buys 3,918 Shares of Shire PLC (SHPG)|
www.americanbankingnews.com - February 24 at 2:42 PM
|First Week of SHPG October 19th Options Trading - Nasdaq|
www.nasdaq.com - February 24 at 8:10 AM
|State of Wisconsin Investment Board Acquires New Stake in Shire PLC (SHPG)|
www.americanbankingnews.com - February 24 at 7:00 AM
|FDA accepts Shire's lanadelumab marketing application for HAE under accelerated review status|
seekingalpha.com - February 23 at 6:02 PM
|FDA Accepts Shire's BLA and Grants Priority Review for Lanadelumab for the Prevention of Attacks in HAE Patients - GlobeNewswire (press release)|
globenewswire.com - February 23 at 8:17 AM
|SHPG April 6th Options Begin Trading - Nasdaq|
www.nasdaq.com - February 23 at 8:17 AM
|Shire: Keep Holding This Controversial Name - Seeking Alpha|
seekingalpha.com - February 23 at 8:17 AM
|FDA Accepts Shire's BLA and Grants Priority Review for Lanadelumab for the Prevention of Attacks in HAE Patients|
feeds.benzinga.com - February 23 at 4:12 AM
|FY2019 Earnings Estimate for Shire PLC Issued By SunTrust Banks (SHPG)|
www.americanbankingnews.com - February 22 at 2:30 PM
|Shire Recognizes Rare Disease Day 2018 with Global Initiatives Focused on Reducing the Time to Diagnosis|
finance.yahoo.com - February 22 at 8:16 AM
|FY2018 EPS Estimates for Shire PLC (SHPG) Decreased by SunTrust Banks|
www.americanbankingnews.com - February 21 at 11:14 AM
|Shire (SHPG) PT Lowered to $190.00 at SunTrust Banks|
www.americanbankingnews.com - February 20 at 8:26 PM
|Reviewing Shire (SHPG) and Novartis (NVS)|
www.americanbankingnews.com - February 20 at 4:28 PM
|Shire (SHPG) Earns "Neutral" Rating from JPMorgan Chase & Co.|
www.americanbankingnews.com - February 20 at 4:06 PM
Shire (NASDAQ:SHPG) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Shire (NASDAQ:SHPG) Income Statement, Balance Sheet and Cash Flow Statement
Shire (NASDAQ SHPG) Stock Chart for Wednesday, March, 21, 2018